Quote:
Originally Posted by jonbxx
There's no real big differences in the purchasing decisions. There are differences in the proportions of each vaccine contracted between the UK and EU but no fundamental differences in what was ordered - the UK and EU bet on the same horses. It seems that speed was the winner here rather than betting on the wrong things.
|
Agreed.
One aspect that may have influenced the UK purchasing pattern was manufacturing location as the UK is keen to build up its vaccine manufacturing base.
Four groups - BioNTech-Pfizer, Moderna, Johnson & Johnson and Sanofi-GlaxoSmithKline — wanted to supply the UK solely from overseas. The other four groups — Oxford-AstraZeneca, Valneva, Novavax and CureVac — accepted funding to help develop and manufacture their products in the UK.